Philip M. Hanno, MD, MPH
Philip M. Hanno, a Urology Times editorial consultant, is professor of urology at the University of Pennsylvania, Philadelphia.
Urologist, former regulator shares FDA insights
Urologist Daniel Shames, MD, has had a unique and varied career, with stops in clinical practice, the FDA, and his current role as a consultant to the pharmaceutical industry. Dr. Shames’ wide-ranging experience brings an insightful perspective on the topics he discusses in this interview: what goes into FDA drug approvals, quality of life endpoints, and the Sunshine Act.
Urologists share how digital ideas became reality
Urologists Alexander Kutikov, MD, and Todd M. Morgan, MD, discuss the impetus behind and drawMD and how they benefit physicians and patients.
Research may yield tailored BPS therapies
The search is on for drugs based on cannabis.
Quality assurance impacts urologists on multiple levels
Urology Times Editorial Consultant Philip M. Hanno, MD, MPH, interviews Roger Dmochowski, MD, about his institution’s Patient Advocacy Reporting System as well as quality improvement and creating algorithms for appropriate care.
New urologic frontiers explored for neurotoxins
OnabotulinumtoxinA (Botox) has earned FDA approval for the treatment of overactive bladder in adults who cannot use or don't adequately respond to anticholinergic drugs, and its potential uses in urology may not end there.
All-female urology practice's mission is to give women choice in care
In this interview, Lora Plaskon, MD, MS, discusses her all-female urology/urogynecology practice's origins, how it differs from mixed-gender practices, and how her unique model fits into today's economy.
Transvaginal mesh controversy: Careful patient selection is key
Howard Goldman, MD, discusses the possible effects of FDA reclassification of transvaginal mesh used for prolapse as well as the importance of adequate surgical training and patient selection.
Progress on interstitial cystitis/bladder pain syndrome: Slow but steady
Articles in this issue of Urology Times highlight two of the more interesting abstracts on interstitial cystitis/bladder pain syndrome (IC/BPS) presented at the 2012 AUA annual meeting in Atlanta. They illustrate the relentless progress being made in the efforts to improve the lives of patients with this difficult-to-treat syndrome.
Preventing recurrent urinary tract infections: Is a vaccine still feasible?
David Klumpp, PhD, and David T. Uehling, MD, explain the challenges inherent in developing a vaccine for UTI and discuss the status of current research.
Role of neurostimulation in urology is on the rise
Kenneth M. Peters, MD, discusses the various forms of neurostimulation, current research efforts, and potential future uses for this modality.